PRENETICS GLOBAL LIMITED

Adjusted free cash flow turned positive only in July and explicitly includes General Catalyst facility funding. The CFO said the facility will fund 70% of acquisition marketing, so positive cash flow is not yet evidence that the standalone business can self-fund growth.

The company itself disclosed that the Customer Investment Agreement's impact is unpredictable and may not function as expected. A failure or change in the arrangement could materially impair liquidity, marketing capacity, and reported growth.

Management's $400 million-plus 2027 outlook is based on current retention curves and excludes new products, but the call provided limited sensitivity analysis for CAC deterioration, churn, subscription mix, returns, or financing costs.

Q2 acquisition marketing was $36.2 million, or 78% of revenue, producing negative $19 million adjusted EBITDA. The assertion that every acquisition dollar generates $1.52 of gross profit does not demonstrate positive fully loaded contribution after fixed costs, royalties, ambassadors, and financing repayments.

Competitive Q&A did not resolve the moat question. Management cited IM8's reported growth versus Thorne and other brands and claimed a better product, but did not provide independent evidence of durable brand superiority, exclusive ingredients, or barriers preventing larger supplement and consumer-health companies from copying the proposition.

July revenue was described inconsistently on the call: the CEO cited $20.9 million for IM8 while the CFO reported $21.4 million for total Prenetics. The discrepancy should be reconciled in filings before relying on the annualized run-rate narrative.